This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It’s also primed to revolutionize the pharmaceutical industry. Pharma companies that truly embrace AI can run parallel clinical trials for the same drug as a single agent or in combinations targeting multiple diseases where the drug is predicted to work. Many pharma companies have changed their CEOs at least once.
announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.
Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
Our fast-growing portfolio encompasses promising therapeutic radioisotopes, specialty SPECT imaging agents and collaborative research for the use of therapeutic radiopharmaceuticals to treat a range of potential disease states. He has more than 30 years of experience in the biotechnology, pharmaceutical and life sciences industries.
AI imaging firm Brainomix has entered into a partnership with German pharmaceutical company Boehringer Ingelheim to improve the care of U.S. patients with fibrosing lung disease.
Ballakur added, “It gives them the features they need to scale their use of AI-enabled pathology and capitalize on the latest innovations that shape our understanding of disease.” The software company is accelerating the transformation to digital pathology to change the way diseases like cancer are understood.
Enigma Biomedical Group USA (EBG-USA) has signed an exclusive agreement to commercialize AbbVie’s tau PET imaging biomarkers for use in patients with suspected neurodegenerative disease. If the evaluations are favorable, EBG-USA has the option to negotiate an exclusive license agreement with AbbVie for the PET ligands.
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
Ac-225 with Curadh is an important step in helping to provide molecularly targeted radiation therapies for patients with cancer, and we look forward to working with them going forward.” “Molecularly targeted radiation is an exciting new field in oncology enabling us to deliver ‘systemic radiotherapy’ to patients with metastatic disease.
Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., In a recent phase III trial , the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease. the company noted.
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. This includes MIMneuro , which offers quantification solutions for dopamine transporter imaging and amyloid imaging.
a clinical-stage biotech developing groundbreaking secretome therapeutics for age and disease-related immune dysfunction, has announced a partnership with Springbok Analytics , a life sciences muscle analytics company. christine.book Thu, 07/25/2024 - 12:44 July 25, 2024 — Immunis, Inc. ,
The statement further noted that digital pathology is modernizing the microscope-based practice, driving a shift to high-resolution images that each contain over 1 billion pixels telling the story of a patient’s disease.
The imaging agent fills an unmet need to identify small lesions, which could allow earlier diagnosis of the disease, noted lead author Brian Shuch, MD, of the University of California, Los Angeles, and colleagues.
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Such contaminants pose regulatory and waste management challenges for pharmaceutical companies, hospitals, and health systems. Under terms of the agreement, NorthStar will supply its high purity, non-carrier added (n.c.a.) Ac-225 to Nucleus.
NeuroShield takes 3D MR images as inputs and automatically calculates brain volumes that can assist physicians in devising treatment plans for patients with neurodegenerative diseases such as Dementia, Alzheimer's' Disease, Parkinson's, and Epilepsy. Globally, over a billion people suffer from neurodegenerative disorders.
Food and Drug Administration (FDA) has granted Clarity Pharmaceuticals fast-track designation for its copper-64 (Cu-64) sarcophagine (SAR) bisPSMA radiopharmaceutical.
head of the Division of Infectious Disease and Global Public Health at UC San Diego School of Medicine , co-director of the university’s Altman Clinical and Translational Research Institute , and study senior author. Ayers , Ph.D.,
This unit will enable us to develop and manufacture patient doses for pharmaceutical or biotechnology companies as well as share our radiopharmaceutical development and commercialization expertise with them where they may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development.
We are delighted to see the inclusion of Cerianna PET in the NCCN breast oncology guidelines, for potential use when oncologists are evaluating metastatic breast cancer patients,” Dr. Mark Hibberd, Chief Medical Officer at GE HealthCare’s Pharmaceutical Diagnostics segment, said. GE HealthCare’s Cerianna , available in the U.S.,
Scott Claunch , President of TerraPower Isotopes, added: "Consistent with TerraPower’s vision of developing innovative solutions to help fight disease using nuclear science, TerraPower Isotopes is thrilled to secure this collaboration with PanTera.
Global pharmaceutical firm UCB developed IB Lab Flamingo's deep-learning computational model which is being integrated into the family of IB Lab Zoo orthopedic AI software modules designed to automatically analyze and extract key disease parameters that are critical for the prevention and treatment of various musculoskeletal conditions.
milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc.,
The ultimate aim is to build a digital healthcare tool that radiologists can use when scanning for other conditions to determine a person’s dementia risk, and to diagnose early stages of related diseases, such as Alzheimer’s.
This partnership exemplifies our commitment to Find, Fight and Follow disease by delivering innovative solutions to improve cancer care, ultimately leading to better patient outcomes." milla1cf Tue, 07/11/2023 - 09:02 July 11, 2023 — Ratio Therapeutics Inc.
Imagine going in for a diagnostic MRI scan and coming out with a progressive, irreversible, and potentially fatal disease. It certainly doesn't help matters that the disease has been linked to gadolinium-based contrast agents, a ubiquitous tool in the MR armamentarium. In 2006 the U.S. report of NSF in 33 dialysis patients at a St.
For those unfamiliar with steatotic liver disease, this is important because Rezdiffra is the first approved treatment for MASH, which if left untreated can progress to cirrhosis, require liver transplantation, and potentially cause death. Rajarshi Banerjee, MD, PhD.
History of liver disease, history of substance abuse disorder, and history of delirium tremens were also extracted from the hospital EMR. What They Did: Retrospective cohort study at a single academic medical center between July 1, 2016 to June 30, 2019. Patients in the study groups were similar regarding demographics.
Finally, respondent hospitals reported the following additional difficulties faced during the war: supply chain disruptions for essential equipment and pharmaceuticals, laboratory test kit shortages, delays in the delivery of crucial medications, and power outages causing problems for appropriate medication storage.
The rise of precision medicine is putting new pressures on diagnostic laboratories to tap into their pathology data, as whole slide images are among the best representations of disease. Concentriq is used by 14 of the top 20 pharmaceutical companies and major diagnostic laboratories worldwide.
The research will produce technical feedback to assist GEHC in assessing the system’s reconstruction methods, image presentation workflow, and clinical benefits for specific pathologies and disease types. MRI GEHC unveiled Signa Champion, a 1.5-tesla,
milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc.
This extraordinary circumstance increased the need for skilled healthcare professionals (particularly those experienced in critical care and disease management). The BLS report attributes this growth to both an aging population and a higher prevalence of heart disease, diabetes, cancer, and other chronic conditions.
The tool also successfully assessed the likelihood of additional conditions accompanying a primary disease (comorbidity index) as well as the chances of an insurance denial. Oermann is a consultant for Sofinnova Partners , a venture-capital firm that specializes in the development of biotechnologies, sustainability, and pharmaceuticals.
For many, machine learning's potential is more than just talk; the power of well-trained, image-augmented AI has already been demonstrated as a useful tool for quality control, disease tracking, tumor segmentation, and making prognosis predictions.
Imaging response criteria are used to define a “treatment response” status, used by the radiologist to evaluate whether the response to therapy is complete or partial or conversely, if the disease is not responding or even progressing. QIBA Profile: CT Tumor Volume Change for Advanced Disease. 1999) J Natl Cancer Inst. 91: 523-528.
We know there are a lot of radiopharmaceuticals for a wide variety of diseases," he said, adding that running clinical trials in a large, multifaceted facility such as BAMF presents the opportunity to "really understand and optimize how to use these kinds of drugs efficiently." led by Harshad Kulkarni, MD, as principal investigator.
Another pharmaceutical company, Wesley Enterprise Inc., Studies funded by pharmaceutical companies are four times more likely to have favorable results than studies from other sources (Lexchin 2003). Pharmaceutical companies can also design trials to get desired results by conducting a trial against a product known to be inferior.
The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR Acute kidney injury. Bayer HealthCare Pharmaceuticals Inc. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. For patients at risk for chronically reduced renal function (e.g. Guerbet LLC.
Cardiovascular care has seen remarkable advancements over the decades, from innovative surgical techniques to cutting-edge pharmaceuticals. Bhatt highlighted the need for inclusivity, particularly in population health, where AI can play a crucial role in identifying at-risk groups and preventing cardiovascular disease.
Technological and pharmaceutical breakthroughs. A group of cardiologists from Cleveland Clinic and Stanford University further tested the chatbot by feeding it questions about preventative cardiology and cardiovascular disease. Promising clinical trials. Solutions to combat provider labor shortages. New treatment paths.
The recommendation was issued by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), the primary body in the European Union responsible for regulating pharmaceuticals. The PRAC noted that no clinical diseases or even symptoms have been reported in connection with gadolinium deposition.
Also, the new online pharmaceutical retail industry is gradually penetrating the market. MRI scans offer many applications in the disease diagnosis like neuroscans, liver scans and cardiac. Further advancements in technology related to MRI have widened its scope to diagnose various diseases.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content